# Opus Genetics, Inc. Common Stock (IRD)

> Opus Genetics, Inc. Common Stock (IRD) trades at $3.99 (-2.21%) as of 7:30:00 PM EST on Nov 20, 2026, +4.45% over the past month. Market cap is $385.65M, with 8.4 days to cover in short interest.

Canonical: https://massive.com/quote/ird
Data as of: 2026-11-21T00:30:00.155Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$3.99** -0.09 (-2.21%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$3.87** -0.12 (-3.03%)
As of 7:30:00 PM EST on Nov 20, 2026 · After hours

## Stock performance

How Opus Genetics, Inc. Common Stock (IRD) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -2.21% |
| 1W | +0.25% |
| 1M | +4.45% |
| YTD | +98.51% |
| 1Y | +99.50% |
| 52-wk range | $1.88 – $7.07 |

From daily closes through Nov 20, 2026.

## Key statistics

Today's trading snapshot for IRD: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $3.89 – $4.05 |
| Open | $4.01 |
| Prev close | $4.08 |
| Volume | 1.19M |
| Market cap | $385.65M |
| Shares out | 96.65M |

## Valuation and profitability ratios

Valuation and profitability ratios for Opus Genetics, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 48.73 |
| P/B | 10.03 |
| P/FCF | — |
| ROE | -355.6% |
| ROA | -143.4% |
| Debt/Equity | 0.90 |
| Div yield | 0.00% |

As of Nov 20, 2026

## Insider trading

[Opus Genetics, Inc. Common Stock (IRD) insider trading](https://massive.com/quote/ird/insider-trading.md): open-market Form 4 buys and sells by Opus Genetics, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Opus Genetics, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 10, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 10, 2026, Opus Genetics, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2026.”
- Oct 21, 2026 · [Executive officer departure](https://massive.com/quote/sec-filings/8-k/executive-departures.md)
  “Opus Genetics, Inc. (the "Company") and Ashwath Jayagopal have agreed that Dr. Jayagopal will transition from his role as the Company's Chief Scientific and Development Officer, effective as of October 19, 2026 (the "Separation Date").”
- Oct 15, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “On October 15, 2026, Opus Genetics, Inc. issued a press release regarding the Company's October 14, 2026 presentations at the Retina in Rio 2026 conference. The presentations covered clinical data from Cohort 1 of the Company's ongoing Phase 1/2 clinical trial of OPGx-BEST1 and clinical data from the Company's ongoing Phase 1/2/3 clinical trial of OPGx-LCA5.”
- Sep 11, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “On September 11, 2026, Opus Genetics, Inc. issued a revised version of the Company's data presentation ... announcing clinical data from Cohort 1 of the Company's ongoing Phase 1/2 clinical trial of OPGx-BEST1 in patients with BEST1-related retinal diseases.”
- Sep 9, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “On September 9, 2026, the Company shared 3- and 6-month results from the low-dose Cohort 1 of BIRD-1, the Company's ongoing Phase 1/2 clinical trial of OPGx-BEST1 in patients with BEST1-related retinal diseases... Following treatment with OPGx-BEST1, all five participants demonstrated clinically meaningful improvement in visual function... Structural improvements were also observed across four participants.”

## IRD short interest

How heavily IRD is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 8.4 |
| Short interest | 10.86M |
| Avg volume | 1.3M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## IRD news

The latest news and headlines about Opus Genetics, Inc. Common Stock (IRD).

- [Opus Genetics, Inc. (IRD) Reports Q3 Loss, Lags Revenue Estimates](https://www.zacks.com/stock/news/3027021/opus-genetics-inc-ird-reports-q3-loss-lags-revenue-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3027021) · Zacks Investment Research · Nov 10, 2026 · negative sentiment
- [Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update](https://www.globenewswire.com/news-release/2026/11/10/3399299/0/en/opus-genetics-announces-financial-results-for-third-quarter-2026-and-provides-corporate-update.html) · GlobeNewswire Inc. · Nov 10, 2026 · positive sentiment
- [Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases](https://www.globenewswire.com/news-release/2026/11/05/3396219/0/en/opus-genetics-completes-dosing-in-cohort-2-of-phase-1-2-clinical-trial-of-opgx-best1-gene-therapy-for-inherited-retinal-diseases.html) · GlobeNewswire Inc. · Nov 5, 2026 · positive sentiment
- [Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia](https://www.globenewswire.com/news-release/2026/10/16/3382714/0/en/opus-genetics-announces-fda-approval-of-phentolamine-ophthalmic-solution-0-75-for-the-treatment-of-presbyopia.html) · GlobeNewswire Inc. · Oct 16, 2026 · positive sentiment
- [Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences](https://www.globenewswire.com/news-release/2026/09/02/3354959/0/en/opus-genetics-to-present-opgx-best1-cohort-1-clinical-data-in-investor-webcast-and-at-upcoming-leading-ophthalmology-conferences.html) · GlobeNewswire Inc. · Sep 2, 2026 · positive sentiment

## About Opus Genetics, Inc. Common Stock

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 28 |
| Listed | Nov 6, 2020 |

[Company website](https://www.opusgtx.com)

## FAQ

### What is the Opus Genetics, Inc. Common Stock (IRD) stock price today?

Opus Genetics, Inc. Common Stock (IRD) is trading at $3.99 (-2.21% on the day) as of 7:30:00 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Opus Genetics, Inc. Common Stock?

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders.

### What is the short interest in IRD?

As of Oct 30, 2026, IRD has 10.86M shares short and 8.4 days to cover.

### What exchange is IRD listed on?

Opus Genetics, Inc. Common Stock (IRD) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time IRD quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=IRD`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Opus Genetics, Inc. Common Stock (IRD) insider trading](https://massive.com/quote/ird/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
